This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dühmke, E. Articles by Diehl, V. Search for Related Content PubMed PubMed Citation Articles by Dühmke, E. Articles by Diehl, V. Social Bookmarking                            What's this?

Low-Dose Radiation Is Sufficient for the Noninvolved Extended-Field Treatment in Favorable Early-Stage Hodgkin’s Disease: Long-Term Results of a Randomized Trial of Radiotherapy Alone

From the Canton Hospital, Basel, Switzerland; Radiotherapy and Internal Medicine Departments, Münich University, Münich; Biometry, Radiotherapy, and Internal Medicine Departments, Cologne University, Cologne; Munster University, Munster; Moabit Hospital, Berlin; Innsbruck University, Innsbruck; Klinikum Passau, Passau; and Pathology Department, Hannover Medical School, Hannover, Germany.

Please visit http://www.jco.org to view the appendices for this article.Address reprint requests to Jeremy Franklin, PhD, Klinik I für Innere Medizin, Cologne University, Josef-Stelzmann-Str 9, 50924 Köln, Germany; email: j.franklin{at}biometrie.uni-koeln.de

PURPOSE: To show that radiotherapy (RT) dose to the noninvolved extended field (EF) can be reduced without loss of efficacy in patients with early-stage Hodgkin’s disease (HD).

PATIENTS AND METHODS: During 1988 to 1994, pathologically staged patients with stage I or II disease who were without risk factors (large mediastinal mass, extranodal lesions, massive splenic disease, elevated erythrocyte sedimentation rate, or three or more involved areas) were recruited from various centers. All patients received 40 Gy total fractionated dose to the involved field areas but were randomly assigned to receive either 40 Gy (arm A) or 30 Gy (arm B) total fractionated dose for the clinically noninvolved EF. No chemotherapy was given. RT films were prospectively reviewed for protocol violations and recurrences retrospectively related to the applied RT.

RESULTS: Of 382 recruited patients, 376 were eligible for randomized comparison, 190 in arm A and 186 in arm B. Complete remission was attained in 98% of patients in each arm. With a median follow-up of 86 months, 7-year relapse-free survival (RFS) rates were 78% (arm A) and 83% (arm B) (P = .093). The upper 95% confidence limit for the possible inferiority of arm B in RFS was 4%. Corresponding overall survival rates were 91% (arm A) and 96% (arm B) (P = .16). The most common causes of death (n = 27) were cardiorespiratory disease/pulmonary embolisms (seven), second malignancy (six), and HD (five). Protocol violation was associated with significantly poorer RFS. Nonirradiated nodes were involved in 42 of 52 reviewed relapses, infield areas in 18, marginal areas in 17, and extranodal sites in 16.

CONCLUSION: EF-RT alone attains good survival rates in favorable early-stage HD. The 30-Gy dose is adequate for clinically noninvolved areas. Protocol violation worsens the subsequent prognosis. Relapse patterns suggest that systemic therapy can reduce the 20% long-term relapse rate.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Engert, J. Franklin, H. T. Eich, C. Brillant, S. Sehlen, C. Cartoni, R. Herrmann, M. Pfreundschuh, M. Sieber, H. Tesch, et al. Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial J. Clin. Oncol., August 10, 2007; 25(23): 3495 - 3502. [Abstract] [Full Text] [PDF]

				O. Landgren, U. Axdorph, T. R. Fears, A. Porwit-MacDonald, C. Wedelin, and M. Bjorkholm A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients Ann. Onc., August 1, 2006; 17(8): 1290 - 1295. [Abstract] [Full Text] [PDF]

				B. Klimm, T. Reineke, H. Haverkamp, K. Behringer, H. T. Eich, A. Josting, B. Pfistner, V. Diehl, and A. Engert Role of Hematotoxicity and Sex in Patients With Hodgkin's Lymphoma: An Analysis From the German Hodgkin Study Group J. Clin. Oncol., November 1, 2005; 23(31): 8003 - 8011. [Abstract] [Full Text] [PDF]

				M. R. Weihrauch, O. Manzke, M. Beyer, H. Haverkamp, V. Diehl, H. Bohlen, J. Wolf, and J. L. Schultze Elevated Serum Levels of CC Thymus and Activation-Related Chemokine (TARC) in Primary Hodgkin's Disease: Potential for a Prognostic Factor Cancer Res., July 1, 2005; 65(13): 5516 - 5519. [Abstract] [Full Text] [PDF]

				A. Josting, L. Nogova, J. Franklin, J.-P. Glossmann, H. T. Eich, M. Sieber, T. Schober, H.-D. Boettcher, U. Schulz, R.-P. Muller, et al. Salvage Radiotherapy in Patients With Relapsed and Refractory Hodgkin's Lymphoma: A Retrospective Analysis From the German Hodgkin Lymphoma Study Group J. Clin. Oncol., March 1, 2005; 23(7): 1522 - 1529. [Abstract] [Full Text] [PDF]

				G. Bonadonna, V. Bonfante, S. Viviani, A. Di Russo, F. Villani, and P. Valagussa ABVD Plus Subtotal Nodal Versus Involved-Field Radiotherapy in Early-Stage Hodgkin's Disease: Long-Term Results J. Clin. Oncol., July 15, 2004; 22(14): 2835 - 2841. [Abstract] [Full Text] [PDF]

				B. M.P. Aleman, A. W. van den Belt-Dusebout, W. J. Klokman, M. B. van't Veer, H. Bartelink, and F. E. van Leeuwen Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin's Disease J. Clin. Oncol., September 15, 2003; 21(18): 3431 - 3439. [Abstract] [Full Text] [PDF]

				S. von Wasielewski, J. Franklin, R. Fischer, K. Hubner, M. L. Hansmann, V. Diehl, A. Georgii, and R. von Wasielewski Nodular sclerosing Hodgkin disease: new grading predicts prognosis in intermediate and advanced stages Blood, May 15, 2003; 101(10): 4063 - 4069. [Abstract] [Full Text] [PDF]